Mave Health develops non-invasive neurostimulation wearables for mental health and cognitive performance, with a focus on improving focus, mood, and stress regulation through short daily sessions. Founded in 2023 by Dhawal Jain, Jai Sharma, and Aman Kumar, the company operates between Bengaluru and San Francisco and recently raised $2.1 million in seed funding to scale its flagship headset, Arc. Its work sits within the consumer and consumer-clinical segment of neurotechnology rather than pharmaceutical development or hospital-based intervention.

The platform is built around transcranial direct current stimulation, or tDCS, delivered through a lightweight headset designed for 20-minute daily use. Mave positions Arc around stimulation of the prefrontal cortex, linking the device to attention, emotional regulation, and stress response. Company materials and recent coverage describe the system as an attempt to package a studied non-invasive neuromodulation modality into a more accessible at-home format, with launches planned in India and the United States.

Mave Health targets conditions and use cases that sit between mental health support and cognitive optimization. Earlier coverage around the company framed the product more directly around depression, while current positioning is broader and centers on focus, mood, and stress regulation. The company is operating through product launch and commercialization pathways rather than regulated drug development, with pre-orders open and shipping planned after a 500-person beta. Its positioning reflects a wider shift toward consumer-facing neurotechnology built on established stimulation methods and packaged for repeated home use.